Galapagos Expands Osteoarthritis Alliance With GSK

Galapagos NV announced that its existing multiyear alliance in osteoarthritis with GlaxoSmithKline (GSK) will be expanded.

GSK said it will bring a drug discovery program against a selected GSK target into the alliance.

Galapagos said the alliance will allow it to progress a disease-modifying drug towards completion of a Phase IIa trial, at which point GSK’s global R&D organization will be responsible for the late-stage development, production and marketing of the drug.